Significant contract signed to manufacture lateral flow device components

Significant contract signed to manufacture lateral flow device components
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Placing of 50,000,000 New Ordinary Shares and Warrants
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation
AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended